Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms.
The characteristic clinical picture of anorexia, tissue wasting, loss of body weight accompanied by a decrease in muscle mass and adipose tissue, and poor performance status that often precedes death has been named the cancer-related anorexia/cachexia syndrome (CACS). Chronic administration of pro-inflammatory cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor (TNF) either alone or in combination, is capable of reproducing the different features of CACS. High serum levels of these cytokines have been found in cancer patients, which seem to correlate with progression of the tumor. This paper describes a series of experimental and clinical studies demonstrating that: (1) high serum levels of some cytokines, including IL-1, IL-6, and TNF, are present in advanced-stage cancer patients, particularly those with CACS; (2) megestrol acetate (MA) has a beneficial therapeutic effect on CACS symptoms, such as appetite, body weight, and quality-of-life; (3) MA downregulates the synthesis and release of cytokines and relieves the symptoms of CACS; (4) cytokines play a key role in the onset of CACS; (5) medroxyprogesterone acetate (MPA) reduces the in vitro production of cytokines and serotonin (5-hydroxytryptamine, 5-HT) by peripheral blood mononuclear cells (PBMC) of cancer patients; and (6) MA and MPA reduce the cisplatin-induced 5-HT release in vitro from PBMC of cancer patients. Based on these results, a clinical study incorporating MA/MPA in combination with chemotherapy or chemoimmunotherapy may be warranted.
Mantovani
G
G
Department of Medical Oncology, University of Cagliari, Italy.
Macciò
A
A
Lai
P
P
Massa
E
E
Ghiani
M
M
Santona
M C
MC
D000855:Anorexia / Q000097:blood / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D019167:Appetite Stimulants / Q000494:pharmacology / Q000627:therapeutic use*; D002100:Cachexia / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000097:blood / Q000187:drug effects*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology / Q000627:therapeutic use*; D019290:Megestrol Acetate / Q000494:pharmacology / Q000627:therapeutic use*; D009363:Neoplasm Proteins / Q000097:blood / Q000187:drug effects*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D045167:Progesterone Congeners / Q000494:pharmacology / Q000627:therapeutic use*; D012701:Serotonin / Q000097:blood